The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Author:Shweta Raskar, Business Development Specialist, Prophecy Market InsightsIntroductionThe Multi-Cancer Early Detection (MCED) Market is witnessing an unprecedented surge as diagnostic ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

Love & Joy Family Clinic announced an expansion of its screening offerings that strengthens the practice's cancer screenin ...

Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay ...

Liquid biopsy technologies are maturing at a rapid pace. They are already being used as a precision medicine tool, helping clinicians match a patient’s cancer to targeted therapies.

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

Liquid biopsy detected targetable mutations in one-third of patients (n = 33) who opted for that test alone.

The researchers also followed a patient for 2.5 years and found that they could detect EML4-ALK in the liquid biopsy a good two months before it was possible to use radiography to confirm the disease.

A patient at Thomas Jefferson University Hospital in Philadelphia has blood drawn for a liquid biopsy last year. The test detected a recurrence of breast cancer. (Jacqueline Larma/AP) ...